


June 2026 Quarterly Business Activity Report & Appendix 4C
23 July 2026
Global Health Limited (ASX: GLH)

Global Health Limited (ASX: GLH) ("Global Health" or "the Company") is pleased to release its Appendix 4C Cash Flow Report for the quarter ended 30 June 2026, and the accompanying Quarterly Business Activity Report. Financial estimates of revenue, expenses and profitability are subject to audit. All figures are in A\$'000. Previous Corresponding Period (PCP) is the June 2025 Quarter.

Financial Highlights


- Customer Receipts up 12.6% to \$9,532K for the 12 months to June-26 (FY25 \$8,463K).
- Operating and investing cashflow of (\$812K) for the 12 months to June-26 represents a reduction of 30% from(\$1,147K) in FY25.
- Technology upgrade and transition to a SaaS business model is now market ready with R&D expense budget reduced by approximately \$700K to \$1.1M in FY2027 (\$1.87M in FY2026).
- Productivity gains from AI adoption across all operating departments provides an additional \$500K saving in expenses in FY2027.

Customer receipts of \$9,532K in the 12 months to June-26 quarter was 12.6% higher than customer receipts in the 12 months to June-25 (\$8,463K).



Operating and investing cashflow. Cash outflows have reduced by 30% mainly due to reductions in staff and contractors as the Company has adopted AI across all aspects of our operations covering sales & marketing, feature design, feature development, testing, on-boarding and support.

The positive cashflow was applied to redeem \$100K of Convertible Notes resulting in a reduced positive cashflow total compared to the PCP. This result also reflects the transition of revenue to MRR as SaaS recurring now represents 31.2% of total ARR (27.8% in FY2025).



The Company is exploring multiple options for the Convertible Notes which are maturing in June 2027 and July 2027. Options include repayments from free cashflow and replacing CN debt with lower cost non-convertible debt.

June 2026 Quarter Activity

In the June quarter, the focus was on completion of software development across multiple platforms:

- Completing the technology upgrade of our three client/server provider applications (on-premises applications) to a single multi-tenanted, configurable platform supporting the SaaS business model.

- Integrating the Heidi Scribe AI Platform to our MasterCare Plus SaaS platform and MasterCare EMR on-premises application with compliance and market release achieved.
- Integrating our HotHealth digital front door (patient portal) and ReferralNet Secure Messaging platform to Best Practice PMS was completed and released to the market.
- Completion of a UI/UX and technology upgrade of our Lifecard Personal Health Record which is in final QA and expected to be released in August.
- Completion and market release of Theatre Management and Bed Flow productivity platforms for overnight and day hospitals.

In the June quarter, 5 new sites went live with MasterCare Plus Case Management SaaS deployment and a further 3 existing customers were upgraded from the legacy (on-premises) MasterCare EMR and PMS (Practice Management System) to MasterCare Plus SaaS.

Forward Outlook and Growth Strategy

Given the market release of our suite of SaaS platforms after approximately \$10M of investment over the last four years, the Company will transition our focus to revenue scaling. This will include expansion to overseas markets with SaaS, AI value-adds and our productivity platforms.

Incremental innovation will be AI driven to deliver further productivity for our customers.

The global outlook from events in the middle east combined with the funding and staffing challenges confronting healthcare providers in Australia is forcing healthcare providers to streamline their costs.

Our SaaS platforms are accessible to a global market. With the launch of online sales channels and low-touch on-boarding, we expect to complement domestic revenue with growing international revenues in FY2027 and beyond.

The accelerating rate of AI capability becoming commercially available and the tremendous productivity gains from implementing AI provides the obvious resolution to the problem.

The Company achieved positive cash-basis EBITDA after expensing all R&D costs, across both the March and June quarters. With the reduction in expenses, and a focus on scaling revenue, the target for FY2027 onwards is to continue EBITDA profitable operations and positive cashflow.

-ENDS-

Required disclosures in accordance with Listing Rule 4.7C

In accordance with Listing Rule 4.7C.1, the operating expenditures of Global Health for the quarter ended 30 June 26 are set out in the table below:

Expense Category	Amount (\$A'000)
Product manufacturing and operating costs	844
Advertising and marketing	26
Leased assets	40
Staff costs	1,322
Administration and corporate costs	173

In accordance with Listing Rule 4.7C.3, payments to related parties and their associates during the quarter totalled **\$81.8K** This related to directors' remuneration.

This announcement was approved for lodgement by the Board.

– ENDS –

For further information please contact:

Global Health Limited

Mathew Cherian

Managing Director

M 0409 099 788

E Mathew.cherian@global-health.com

About Global Health Limited

Located in Melbourne, Victoria the company is ISO27001 compliant.

To learn more about Global Health please visit: www.global-health.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Global Health Limited

ABN

75 091 377 892

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1.1	Receipts from customers	2,519	9,532
1.2	Payments for		
	(a) research and development		
	(b) product manufacturing and operating costs	(844)	(5,170)
	(c) advertising and marketing	(26)	(113)
	(d) leased assets	(40)	(153)
	(e) staff costs	(1,322)	(4,813)
	(f) administration and corporate costs	(173)	(674)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	14
1.5	Interest and other costs of finance paid	(45)	(177)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	0	764
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	70	(790)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	0	(11)
(d) investments	-	-
(e) intellectual property	-	(11)
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	-	-
(j) investments	-	-
(k) intellectual property	-	-
(l) other non-current assets	-	-
2.3 Cash flows from loans to other entities	0	0
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	0	(22)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Net proceeds from borrowings	422	649
3.6	Net repayment of borrowings	(125)	(374)
3.7	Repayment of Convertible Notes	(100)	(100)
3.8	Transaction costs related to loans and borrowings	-	-
3.9	Dividends paid	-	-
3.10	Other (provide details if material)	-	-
3.11	Net cash from / (used in) financing activities	197	175

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	475	1,383
4.2	Net cash from / (used in) operating activities (item 1.9 above)	70	(790)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	(22)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	197	175
4.5	Effect of movement in exchange rates on cash held	(3)	(7)
4.6	Cash and cash equivalents at end of period	739	739

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	739	475
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	739	475

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.2	Aggregate amount of payments to related parties and their associates included in item 2 **	82

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

** Payments associated with item 6.1 relate to directors' fees/directors' remuneration.*

*** Payments associated with item 6.2 relate to a loan to an associate company.*

7. Financing facilities		
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	Loan facilities	946
7.2	Credit standby arrangements	9
7.3	Other (please specify)	1,177
7.4	Total financing facilities	2,032
7.5	Unused financing facilities available at quarter end	NIL
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

7.1

Lender: Various sophisticated investors – Convertible Note

Interest rate: 12% per annum

Maturity date: 17 June 2027

7.2

Lender: Australia and New Zealand Banking Group Limited (ANZ)

Company Credit Card Facility

Interest rate: Up to 8-week Interest free period. Otherwise, 17.74% per annum on purchases if unpaid by the due date. 19.24% per annum on cash advances.

Secured/unsecured: Unsecured

7.3

Lender: HP Financial Services (Australia) Pty Ltd

Interest rate: 12.748% per annum

Maturity date: September 2026

Secured/unsecured: Unsecured

Lender: De Lage Landen Pty Ltd

Interest rate: 8.228% per annum

Maturity date: June 2030

Secured/unsecured: Unsecured

7.3

Lender: Westpac Insurance Premium Funding

Interest rate: flat 3%

Maturity Date: February 2027

Secured/unsecured: Unsecured

7.3

Lender: Westpac Insurance Premium Funding

Interest rate: flat 3.6%

Maturity Date: June 2027

Secured/unsecured: Unsecured

7.3

Lender: Attvest Finance Pty Ltd

Interest rate: flat 5.77%

Maturity Date: January 2027

Secured/unsecured: Unsecured

8. Estimated cash available for future operating activities		\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	70
8.2	Cash and cash equivalents at quarter end (item 4.6)	739
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	739
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: NA		
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: NA		
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: NA		
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 July 2026

Authorised by: Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.